From a pharmacological perspective, Cannabis' (and CBD's) diverse receptor profile explains its potential application for such a wide variety of medical conditions. Cannabis contains more than 400 different chemical compounds, of which 61 are considered cannabinoids, a class of compounds that act upon endogenous cannabinoid receptors of the body [11]. Cannabinoid receptors are utilized endogenously by the body through the endocannabinoid system, which includes a group of lipid proteins, enzymes, and receptors that are involved in many physiological processes. Through its modulation of neurotransmitter release, the endocannabinoid system regulates cognition, pain sensation, appetite, memory, sleep, immune function, and mood among many other bodily systems. These effects are largely mediated through two members of the G-protein coupled receptor family, cannabinoid receptors 1 and 2 (CB1 and CB2)[12, 8]. CB1 receptors are found in both the central and peripheral nervous systems, with the majority of receptors localized to the hippocampus and amygdala of the brain. Physiological effects of using cannabis make sense in the context of its receptor activity as the hippocampus and amygdala are primarily involved with regulation of memory, fear, and emotion. In contrast, CB2 receptors are mainly found peripherally in immune cells, lymphoid tissue, and peripheral nerve terminals [9].
Extinction learning: One way we get over anxiety is through “extinction learning,” or learning to let go of triggers when there’s nothing left to fear. These experiments often train test subjects to associate something harmless with something painful, and then measure how long it takes to stop fearing the harmless trigger after they stop delivering pain. This is particularly relevant for people suffering from PTSD: 

Many people may be concerned that our cannabis oils are low in THC, as compared with other cannabis extracts or concentrates (such as hash, shatter, or BHO). The most important thing to keep in mind is that it is not the potency (% or mg/mL THC) that is important, but rather the total dose in mg THC (amount of cannabis extract in mg × potency of cannabis extract % or mg/mL).
Most human studies of CBD have been done on people who have seizures, and the FDA recently approved the first CBD-based drug, Epidiolex, for rare forms of epilepsy. Clinical trials for other conditions are promising, but tiny. In one Brazilian study published in 2011 of people with generalized social anxiety disorder, for example, taking a 600-mg dose of CBD (higher than a typical dose from a tincture) lessened discomfort more than a placebo, but only a dozen people were given the pill.
Our hemp oil is cold pressed and cold filtered with no added preservatives or dyes. Each 15-millilitre serving (1 tablespoon) contains 10 grams of omega-3 and omega-6. The light, nutty taste is perfect drizzled over veggies, on pasta, or even on your popcorn for movie night. You can also add it to salad dressings, sauces, dips, and shakes. Use this light green oil as a substitute for other oils in recipes that aren’t heated above 300 °F (150 °C). Not recommended for frying.
Marijuana can produce acute psychotic episodes at high doses, and several studies have linked marijuana use to increased risk for chronic psychosis in individuals with specific genetic risk factors. Research suggests that these effects are mediated by THC, and it has been suggested that CBD may mitigate these effects.xxxi There have been a few small-scale clinical trials in which patients with psychotic symptoms were treated with CBD, including case reports of patients with schizophrenia that reported conflicting results; a small case study in patients with Parkinson’s disease with psychosis, which reported positive results; and one small randomized clinical trial reporting clinical improvement in patients with schizophrenia treated with CBD.xxxii Large randomized clinical trials would be needed to fully evaluate the therapeutic potential of CBD for patients with schizophrenia and other forms of psychosis.